• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Latest News

Bimekizumab vs. Risankizumab: BE BOLD Study Insights with Jeff Stark
Bimekizumab vs. Risankizumab: BE BOLD Study Insights with Jeff Stark

October 15th 2024

The study design emphasizes elevated endpoints, particularly joint health, ensuring that the most relevant outcomes are prioritized for patient care.

FDA Clears Accure’s Laser System for Long-Term Treatment of Acne
FDA Clears Accure’s Laser System for Long-Term Treatment of Acne

October 15th 2024

ALPHA Study Finds Alitretinoin Is Fast, Effective for CHE Treatment
ALPHA Study Finds Alitretinoin Is Fast, Effective for CHE Treatment

October 15th 2024

Exploring Roflumilast Cream 0.3% for Refractory Palmoplantar Pustulosis
Exploring Roflumilast Cream 0.3% for Refractory Palmoplantar Pustulosis

October 15th 2024

Almirall Completes Decentralized Regulatory Approval Procedure for Efinaconazole in Europe
Almirall Completes Decentralized Regulatory Approval Procedure for Efinaconazole in Europe

October 15th 2024

Navigating CSU Diagnosis: Best Practices
Meet the 2024 Quarterly Editor in Chiefs
Subscribe Now for Free - eNL
Explore Our Conference Coverage
Subscribe for Free - Print
Stay Informed!
Don't miss the latest in dermatology news
2

Conference Coverage

View All
Conference Speaker Sneak Peek: Elevate-Derm
Conference Speaker Sneak Peek: Elevate-Derm

October 14th 2024

Highly Prevalent, Scarcely Supported: Common Skin Issues Remain Underserved
Highly Prevalent, Scarcely Supported: Common Skin Issues Remain Underserved

October 10th 2024

Phase 2b Trial Reinforces Zasocitinib’s Safety Profile
Phase 2b Trial Reinforces Zasocitinib’s Safety Profile

October 8th 2024

Tralokinumab Shows Long-Term Efficacy for AD in Sensitive Areas
Tralokinumab Shows Long-Term Efficacy for AD in Sensitive Areas

October 7th 2024

Latest Videos

All News

© 2024 MJH Life Sciences

All rights reserved.